Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V® USA study

Journal of Interventional Cardiology

Volumn 25, Issue 6, 2012, Pages 565-575

  Hermiller, James B ^a   Rutledge, David R ^b   Gruberg, Luis ^c   Katopodis, John N ^d   Lombardi, William ^e   Mao, Vivian W ^b   Zhao, Weiying ^b   Sharma, Samin K ^f   Tamboli, Hoshedar P ^g   Wang, Jin ^b   Jonnavithula, Lalitha ^b   Sudhir, Krishnankutty ^b   Krucoff, Mitchell W ^h  

^a St Vincent Heart Center of Indiana   (United States)

^b ABBOTT VASCULAR   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d Tallahassee Research Institute   (United States)

^e St Joseph's Hospital   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g Bay Area Cardiology Associates   (United States)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; EVEROLIMUS; THIENOPYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVASCULARIZATION; RISK ASSESSMENT; STENT THROMBOSIS; UNITED STATES;

ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; SIROLIMUS; THROMBOSIS; UNITED STATES;

EID: 84871282809     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2012.00766.x     Document Type: Article

References (37)

1. Kedhi E, Joesoef KS, McFadden E, et al,. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet 2010; 375 (9710): 201-209.
2. Lotan C, Meredith IT, Mauri L, et al,. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-Month data from the E-Five registry. JACC Cardiovasc Interv 2009; 2 (12): 1227-1235.
3. McFadden EP, Stabile E, Regar E, et al,. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364 (9444): 1519-1521.
4. Ong AT, McFadden EP, Regar E, et al,. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45 (12): 2088-2092.
5. Joner M, Nakazawa G, Finn AV, et al,. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52 (5): 333-342.
6. ® USA condition-of-approval post market study. JACC Cardiovasc Interv 2011; 4 (1298): 1298-1309.
7. Onuma Y, Serruys PW, Kukreja N, et al,. Randomized comparison of everolimus- and paclitaxel-eluting stents: Pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials. Eur Heart J 2010; 31 (9): 1071-1078.
8. ® everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: The SPIRIT II trial. Circ Cardiovasc Interv 2009; 2 (4): 339-347.
9. ® Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials. JACC Cardiovasc Interv 2010; 3 (12): 1229-1239.
10. ® Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol 2011; 58 (1): 19-25.
11. Allocco D,. Everolimus-eluting stents: Update on current clinical studies. Medical Devices: Evidence Res 2011; 4: 91-98.
12. Serruys P, Ruygrok P, Neuzner J, et al,. A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. EuroIntervention 2006; 2: 286-294.
13. Stone GW, Midei M, Newman W, et al,. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial. JAMA 2008; 299 (16): 1903-1913.
14. Antman EM, Hand M, Armstrong PW, et al,. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines-developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008; 117 (2): 296-329.
15. Cutlip DE, Windecker S, Mehran R, et al,. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
16. Mendis S, Thygesen K, Kuulasmaa K, et al,. World Health Organization definition of myocardial infarction: 2008-09 Revision. Int J Epidemiol 2010; 40: 139-146.
17. Gomez-Lara J, Heo JH, Brugaletta S, et al,. Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents. Am Heart J 2011; 162 (6): 1069-1079, e2.
18. Rao AK, Pratt C, Berke A, et al,. Thrombolysis in myocardial infarction (TIMI) trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11 (1): 1-11.
19. Smith SC, Jr. , Feldman TE, Hirshfeld JW, Jr. , et al,. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113 (1): 156-175.
20. Stone GW, Midei M, Newman W, et al,. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 2009; 119 (5): 680-686.
21. Silber S, Windecker S, Vranckx P, et al,. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-Year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011; 377 (9773): 1241-1247.
22. Smits PC, Kedhi E, Royaards KJ, et al,. 2-Year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: A randomized open label trial). J Am Coll Cardiol 2011; 58 (1): 11-18.
23. Lasala JM, Cox DA, Dobies D, et al,. Drug-eluting stent thrombosis in routine clinical practice: Two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ Cardiovasc Interv 2009; 2 (4): 285-293.
24. Daemen J, Wenaweser P, Tsuchida K, et al,. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369 (9562): 667-678.
25. Serruys PW, Silber S, Garg S, et al,. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363 (2): 136-146.
26. Stone GW, Moses JW, Ellis SG, et al,. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356 (10): 998-1008.
27. Grube E, Dawkins KD, Guagliumi G, et al,. TAXUS VI 2-year follow-up: Randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J 2007; 28 (21): 2578-2582.
28. Byrne RA, Kastrati A, Tiroch K, et al,. 2-Year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. J Am Coll Cardiol 2010; 55 (23): 2536-2543.
29. Stone GW,. SPIRIT III two year clinical follow-up. EuroPCR 2008, Barcelona, Spain, 2008.
30. Stone GW, Kedhi E, Kereiakes DJ, et al,. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 2011; 124 (8): 893-900.
31. Mitsuuchi Y, Johnson SW, Selvakumaran M, et al,. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 2000; 60 (19): 5390-5394.
32. ® Everolimus Eluting Coronary Stent System). J Am Coll Cardiol 2010; 56 (25): 2084-2089.
33. Widimsky P, Rychlik I,. Renal disease and acute coronary syndrome. Heart 2010; 96 (1): 86-92.
34. Hage FG, Venkataraman R, Zoghbi GJ, et al,. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009; 53 (23): 2129-2140.
35. Best PJ, Berger PB, Davis BR, et al,. Impact of mild or moderate chronic kidney disease on the frequency of restenosis: Results from the PRESTO trial. J Am Coll Cardiol 2004; 44 (9): 1786-1791.
36. ® everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions. JACC Cardiovasc Interv 2011; 4 (2): 168-175.
37. von Birgelen C, Basalus MW, Tandjung K, et al,. A randomized controlled trial in second-generation zotarolimus-eluting resolute stents versus everolimus-eluting Xience V stents in real-world patients: The TWENTE trial. J Am Coll Cardiol 2012; 59 (15): 1350-1361.